Lead optimization of 8-(methylamino)-2-oxo-1,2-dihydroquinolines as bacterial type II topoisomerase inhibitors.Ushiyama, F., Amada, H., Mihara, Y., Takeuchi, T., Tanaka-Yamamoto, N., Mima, M., Kamitani, M., Wada, R., Tamura, Y., Endo, M., Masuko, A., Takata, I., Hitaka, K., Sugiyama, H., Ohtake, N.
(2020) Bioorg Med Chem 28: 115776-115776
- PubMed: 33032189
- DOI: https://doi.org/10.1016/j.bmc.2020.115776
- Primary Citation of Related Structures:
- PubMed Abstract:
The global increase in multidrug-resistant pathogens has caused severe problems in the treatment of infections. To overcome these difficulties, the advent of a new chemical class of antibacterial drug is eagerly desired. We aimed at creating novel antibacterial agents against bacterial type II topoisomerases, which are well-validated targets. TP0480066 (compound 32) has been identified by using structure-based optimization originated from lead compound 1, which was obtained as a result of our previous lead identification studies. The MIC 90 values of TP0480066 against methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococci (VRE), and genotype penicillin-resistant Streptococcus pneumoniae (gPRSP) were 0.25, 0.015, and 0.06 μg/mL, respectively. Hence, TP0480066 can be regarded as a promising antibacterial drug candidate of this chemical class.
Taisho Pharmaceutical Co., Ltd, 1-403 Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan. Electronic address: email@example.com.